CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO...

... with the goal of providing ground-breaking advancements in the treatment of HIV." PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a ...

http://ift.tt/1eMm6d4